We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-8.66%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$419M
AUM Growth
-$20.7M
Cap. Flow
+$25.1M
Cap. Flow %
5.99%
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$8.5M
2
URGN icon
UroGen Pharma
URGN
+$6.67M
3
BHVN icon
Biohaven
BHVN
+$3.95M
4
ALKS icon
Alkermes
ALKS
+$2.96M
5
SLRN
ACELYRIN
SLRN
+$2.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$2.44M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$2.25M
3
BNTX icon
BioNTech
BNTX
+$1.57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.56M
5
CATX icon
Perspective Therapeutics
CATX
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 85.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
26
BioCryst Pharmaceuticals
BCRX
$2.28B
$4.35M 1.04%
704,500
-5,000
-0.7% -$27.6K
IPSC icon
27
Century Therapeutics
IPSC
$364M
$4.35M 1.04%
1,704,232
+396,825
+30% +$1.25M
ALEC icon
28
Alector
ALEC
$168M
$4.14M 0.99%
912,928
– –
TSVT
29
DELISTED
2seventy bio
TSVT
$4.05M 0.97%
1,050,709
-153,342
-13% -$691K
RCUS icon
30
Arcus Biosciences
RCUS
$3.55B
$3.86M 0.92%
253,217
+21,500
+9% +$347K
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$3.23M 0.77%
130,175
– –
PODD icon
32
Insulet
PODD
$11.5B
$3.21M 0.77%
15,900
– –
KROS icon
33
Keros Therapeutics
KROS
$199M
$3.1M 0.74%
67,754
– –
SLRN
34
DELISTED
ACELYRIN
SLRN
$3.06M 0.73%
693,609
+491,022
+242% +$2.3M
ALKS icon
35
Alkermes
ALKS
$8.22B
$2.91M 0.7%
+120,700
New +$2.96M
STOK icon
36
Stoke Therapeutics
STOK
$1.8B
$2.8M 0.67%
207,427
+62,427
+43% +$843K
ATXS
37
DELISTED
Astria Therapeutics
ATXS
$2.49M 0.6%
274,165
+50,900
+23% +$497K
BCYC
38
Bicycle Therapeutics
BCYC
$269M
$2.47M 0.59%
122,200
– –
CATX icon
39
Perspective Therapeutics
CATX
$332M
$2.31M 0.55%
231,634
-78,730
-25% -$1.14M
ARAY icon
40
Accuray
ARAY
$32M
$2.22M 0.53%
1,222,358
– –
ITOS
41
DELISTED
iTeos Therapeutics
ITOS
$2.14M 0.51%
144,360
+45,800
+46% +$656K
SPRY icon
42
ARS Pharmaceuticals
SPRY
$509M
$2.04M 0.49%
239,194
– –
MDWD icon
43
MediWound
MDWD
$181M
$1.93M 0.46%
124,479
-64,274
-34% -$1.06M
BWAY
44
Brainsway
BWAY
$611M
$1.81M 0.43%
595,310
– –
INGN icon
45
Inogen
INGN
$175M
$1.7M 0.41%
208,790
– –
IMTX icon
46
Immatics
IMTX
$1.18B
$1.68M 0.4%
145,000
– –
RGLS
47
DELISTED
Regulus Therapeutics
RGLS
$1.6M 0.38%
895,200
-175,348
-16% -$407K
PRQR icon
48
ProQR Therapeutics
PRQR
$243M
$1.5M 0.36%
905,582
– –
CMPS
49
Compass Pathways
CMPS
$1.53B
$1.47M 0.35%
243,210
– –
ALLO icon
50
Allogene Therapeutics
ALLO
$649M
$1.41M 0.34%
+605,100
New +$1.79M
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, DAFNA Capital Management held 85 positions worth $419M, down 4.7% from $439M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $25.1M of net new capital in Q2 2024, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was UroGen Pharma: 469,000 shares worth $7.87M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Procept Biorobotics, an estimated $2.44M trimmed.

  • DAFNA Capital Management's largest Q2 2024 buy was UroGen Pharma: 469,000 shares worth $7.87M.
  • DAFNA Capital Management added most to AtriCure in Q2 2024, an estimated $8.5M increase.
  • DAFNA Capital Management's biggest Q2 2024 reduction was Procept Biorobotics, cutting an estimated $2.44M.
  • DAFNA Capital Management fully exited BioNTech in Q2 2024, selling an estimated $1.57M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $419M portfolio in Q2 2024.
  • DAFNA Capital Management opened 13 new positions and closed 2 in Q2 2024.
  • DAFNA Capital Management's portfolio value fell 4.7% quarter-over-quarter to $419M.

Based on DAFNA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.